Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary intervention

In the July 2016 issue of JACC: Cardiovascular Interventions, Koskinas et al. used observational registry data to compare the safety and efficacy outcomes of triple antithrombotic therapy (TAT) prescribed for one month versus longerduration TAT in patients undergoing percutaneous coronary intervention (PCI) with a clear indication for oral anticoagulation (OAC) therapy (1).